Medicare Premiums and Aduhelm: The Political Headache Continues

CMS took pains in its final national coverage determination to try to mend fences with FDA; how the NCD will play with Medicare recipients remains an open question, especially since the Alzheimer’s-induced premium hikes remain in effect.

brain puzzle
CMS HAS YET TO PUZZLE OUT HOW TO LOWER MEDICARE PREMIUMS EVEN AFTER BIOGEN CUT ADUHELM’S PRICE AND MEDICARE OPTED NOT TO COVER THE PRODUCT OUTSIDE OF TRIALS. • Source: Getty

More from Medicare

More from Government Payers